XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Liquidity
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Liquidity Disclosure [Text Block]
2.
Liquidity
 
The Company has
not
generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities.
No
assurance can be given that any such financing will be available when needed, or at all, or that the Company's research and development efforts will be successful.
 
The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with
third
parties and other strategic alliances and business transactions. The Company does
not
have any commitments to obtain additional funds and
may
be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with
third
parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it
may
receive lower consideration upon commercialization of such products than if it had
not
entered such arrangements or if it entered into such arrangements at later stages in the product development process.
 
Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company's product candidates become approved products and how significant their market share will be, some of which are outside of the Company's control. The length of time and cost of developing and commercializing the Company's product candidates and/or failure of them at any stage of the approval process will materially affect the Company's financial condition and future operations. The Company believes its cash and cash equivalents as of
September 
30,
2020
are sufficient to fund operations into the
fourth
quarter of
2022.